Three months ago, the world of stroke medication had been thrown into disarray with the introduction of the World Health Organization’s new guidelines.
Although there was much good news in this week’s publication of the guidelines, it is not enough.
In fact, the guidelines contain many errors.
I am particularly concerned about the two new categories of stroke medications that the WHO has now created.
First, it does not distinguish between “stroke medication treatment” and “stroke medications medication treatment,” a mistake that could have a serious impact on the treatment of stroke.
This mistake was made to create a clear distinction between two different classes of stroke treatments.
Second, it fails to differentiate between the two major types of stroke therapy, the two types of treatment that can help patients manage their stroke: antiepileptic and antithrombotic medications.
Antiepiles have long been recognized as effective at treating stroke but the current guidelines do not consider antiepitist medications as part of the stroke treatment spectrum.
Antithrombulbs are the next best thing, but it is clear that they are not part of this treatment spectrum either.
Third, it includes only two stroke treatment groups, and there is no indication that stroke medications treat all patients equally.
This is a glaring omission.
There are other treatment groups with less common but equally important effects on stroke.
As a result, the stroke medication treatment guidelines are completely inadequate and will not help patients with all types of strokes.
This means that the guidelines will not only increase the costs of stroke care, but also may put patients at increased risk of stroke-related complications.
These complications include heart attacks, stroke-associated death, and stroke-induced disability.
These are all serious issues that need urgent attention and will only worsen the disease.
The recommendations should not be a new development, and they should not have been introduced to address a significant and important problem.
Instead, the WHO guidelines are a dangerous step backward.
It is time to review the stroke medications treatment guideline to ensure that the information is accurate, and to update the guidelines as needed.
Guidelines should not add to the cost of care for patients, but instead should be used to inform the best way to help patients and their families.